J&J asks FDA to approve COVID-19 booster shots

Johnson & Johnson said Tuesday it asked the Food and Drug Administration to approve a booster shot of its one-dose COVID-19 vaccine for people 18 years and older.

Why it matters: The company last month released data from a global study on the efficacy of a booster shot for its vaccine, which showed that the protection offered by its coronavirus vaccine was strengthened by a second dose.

What they’re saying: “Our clinical program has found that a booster of our COVID-19 vaccine increases levels of protection for those who have received our single-shot vaccine to 94 percent,” said Mathai Mammen, head of research for J&J’s Janssen unit.

The big picture: The U.S. government last month approved Pfizer booster shots for those 65 and older, workers in high-risk jobs and other vulnerable Americans.

Yes, but: Moderna’s and J&J’s approval may be more complicated than Pfizer’s because there is less data from booster shot trials for their vaccines.

Go deeper: Data holes could complicate Moderna and J&J booster shot process

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on print
Share on email
Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on print
Share on email